Reliance Global Group settles executive equity awards, plans acquisition
Reliance Global Group announces cash settlements for executive equity awards and a new acquisition plan, signaling a strategic shift in its business model.
FMC Corp amends credit agreement amid India business sale
FMC Corp updates its credit agreement to utilize proceeds from the sale of its Indian operations for debt repayment and other corporate needs.
Unusual Machines Completes Acquisition of DroneNX LLC
Unusual Machines, Inc. has finalized its acquisition of DroneNX LLC, marking a significant move in the radio and TV broadcasting equipment industry.
Stem, Inc. Faces NYSE Delisting Over Compliance Issues
Stem, Inc. notifies NYSE of non-compliance with listing standards, plans to submit a business plan to regain compliance within 18 months.
Sunrise Realty Trust stockholders approve merger-related stock issuance
Sunrise Realty Trust stockholders approve significant stock issuance for merger with Southern Realty Trust, alongside a prorated dividend announcement.
NOVAGOLD Resources updates shareholders on acquisition plans
NOVAGOLD Resources Inc. updates on its acquisition of a 40% interest in Donlin Gold LLC, aiming for 100% ownership and impacting the gold and silver ores sector.
Peraso Inc. secures $10 million in private placement deal
Peraso Inc. has entered a $10 million private placement agreement with Nant Capital, allowing for strategic board appointments and financial growth.
Nathan's Famous Completes Merger with Smithfield Foods
Nathan's Famous, Inc. has merged with Smithfield Foods, becoming a wholly-owned subsidiary, impacting the retail-eating places industry.
Capstone Energy Plus appoints Brandon Schwertner to Board
Capstone Energy Plus, Inc. has appointed Brandon Schwertner to its Board of Directors, enhancing leadership as it aims for growth in the energy sector.
SHF Holdings announces potential merger with Opifex Media
SHF Holdings, Inc. reveals a potential business combination with Opifex Media Inc., a significant move in the finance services sector.
K&F Growth Acquisition Corp. II Issues Class A Shares
K&F Growth Acquisition Corp. II has issued 9,583,332 Class A shares, moving towards a business combination and impacting the blank check industry.
Braemar Hotels & Resorts nominates eight for board election
Braemar Hotels & Resorts Inc. announces nomination of eight new directors to strengthen leadership amid competitive real estate investment trust sector.
Oaktree Acquisition Corp. III Life Sciences extends business deadline
Oaktree Acquisition Corp. III Life Sciences extends its deadline to complete a business combination to November 25, 2026, impacting its strategic direction.
Procaccianti Hotel REIT modifies loan, extends maturity date
Procaccianti Hotel REIT, Inc. modifies loan terms to increase borrowing capacity and extends maturity date, supporting renovations at Hotel Indigo.
Zymeworks Enters Major Collaboration with Roche for ZW209
Zymeworks has signed a collaboration agreement with Roche, granting exclusive rights to develop ZW209, a promising cancer treatment, with significant financial incentives.
UY Scuti Acquisition Corp. Enters Merger Agreement with Isdera
UY Scuti Acquisition Corp. announces a merger with Isdera Group Limited, a significant step in the blank check industry.
Worthington Steel's Kloeckner Agreement Fails Shareholder Vote
Worthington Steel's proposed agreement with Kloeckner fails to gain shareholder approval, impacting future strategies and operational plans.
Arcosa Completes Merger with CRH Americas, Changes Control
Arcosa, Inc. has finalized its merger with CRH Americas, transforming its operational structure and impacting the fabricated structural metal products industry.
Transocean announces merger with Valaris, pending approvals
Transocean Ltd. reveals a merger with Valaris Limited, a strategic move in the drilling oil and gas wells sector, pending shareholder approvals.
Oric Pharmaceuticals updates on enozertinib program at ESMO
Oric Pharmaceuticals presents promising enozertinib data and plans Phase 3 trial for 2027, impacting the oncology pharmaceutical sector.